ALVO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Alvotech SA (ALVO) is not a strong buy at the moment for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The stock is currently in a holding pattern due to pending U.S. approvals in Q4 2026, high leverage, and financial flexibility concerns. While the company has shown improvements in financial metrics, the lack of positive trading signals, neutral sentiment from hedge funds and insiders, and recent analyst downgrades suggest a cautious approach. Holding the stock or waiting for clearer catalysts is recommended.
The MACD is positive and contracting, indicating a neutral to slightly bullish trend. RSI is neutral at 52.917, and moving averages are converging, suggesting no clear directional trend. Key support is at $3.4, and resistance is at $3.85. The stock's short-term trend shows a 70% chance of a slight decline (-0.88%) in the next day and a larger drop (-5.4%) in the next week, but a potential recovery (+4.6%) in the next month.
Net income and EPS improved significantly YoY, with net income up 62.09% and EPS up 65.22%. Gross margin also increased by 33.84%, showing operational improvements.
High leverage and ongoing R&D and Capex plans raise concerns about financial flexibility. Pending U.S. approvals in Q4 2026 create uncertainty. Analysts have recently lowered price targets, with one maintaining an Underweight rating and another highlighting financial risks.
In Q4 2025, the company demonstrated improved financial performance, with revenue increasing to $168.89M (+10.14% YoY), net income improving to -$108.55M (+62.09% YoY), EPS increasing to -0.38 (+65.22% YoY), and gross margin rising to 63.72% (+33.84% YoY). Despite these improvements, the company remains unprofitable.
Analysts have recently lowered price targets, with Deutsche Bank reducing it to $4 from $8 and Barclays lowering it to $4 from $5, both maintaining cautious ratings (Hold and Underweight, respectively). UBS lowered its target to $6 from $10 but remains optimistic with a Buy rating, citing confidence in the company's remediation plan and long-term potential.
